Free Trial
NASDAQ:LFCR

Lifecore Biomedical (LFCR) Stock Price, News & Analysis

Lifecore Biomedical logo
$6.90 -0.10 (-1.43%)
As of 10:12 AM Eastern

About Lifecore Biomedical Stock (NASDAQ:LFCR)

Key Stats

Today's Range
$6.87
$7.02
50-Day Range
$5.10
$7.29
52-Week Range
$3.68
$7.99
Volume
19,022 shs
Average Volume
232,572 shs
Market Capitalization
$255.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Hold

Company Overview

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Lifecore Biomedical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
32nd Percentile Overall Score

LFCR MarketRank™: 

Lifecore Biomedical scored higher than 32% of companies evaluated by MarketBeat, and ranked 707th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lifecore Biomedical has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lifecore Biomedical has received no research coverage in the past 90 days.

  • Read more about Lifecore Biomedical's stock forecast and price target.
  • Earnings Growth

    Earnings for Lifecore Biomedical are expected to grow in the coming year, from ($0.91) to ($0.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lifecore Biomedical is -12.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lifecore Biomedical is -12.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lifecore Biomedical has a P/B Ratio of 18.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.75% of the float of Lifecore Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Lifecore Biomedical has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lifecore Biomedical has recently decreased by 2.69%, indicating that investor sentiment is improving.
  • Dividend Yield

    Lifecore Biomedical does not currently pay a dividend.

  • Dividend Growth

    Lifecore Biomedical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.75% of the float of Lifecore Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Lifecore Biomedical has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lifecore Biomedical has recently decreased by 2.69%, indicating that investor sentiment is improving.
  • News Sentiment

    Lifecore Biomedical has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Lifecore Biomedical this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for LFCR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Lifecore Biomedical to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lifecore Biomedical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $284,852.00 in company stock.

  • Percentage Held by Insiders

    32.20% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    83.36% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lifecore Biomedical's insider trading history.
Receive LFCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter.

LFCR Stock News Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
Lifecore appoints Salus as chief legal, administration officer
See More Headlines

LFCR Stock Analysis - Frequently Asked Questions

Lifecore Biomedical's stock was trading at $7.43 at the start of the year. Since then, LFCR stock has decreased by 5.9% and is now trading at $6.9950.
View the best growth stocks for 2025 here
.

Lifecore Biomedical, Inc. (NASDAQ:LFCR) issued its quarterly earnings results on Thursday, April, 3rd. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.05. The firm earned $35.15 million during the quarter, compared to analyst estimates of $33.23 million. Lifecore Biomedical had a negative trailing twelve-month return on equity of 315.23% and a negative net margin of 12.52%.
Read the conference call transcript
.

Lifecore Biomedical's top institutional investors include Bank of New York Mellon Corp (0.23%), Rhumbline Advisers (0.07%), Hurley Capital LLC (0.01%) and MassMutual Private Wealth & Trust FSB (0.01%). Insiders that own company stock include Wynnefield Partners Small Cap and Paul Josephs.
View institutional ownership trends
.

Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lifecore Biomedical investors own include JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Visa (V).

Company Calendar

Last Earnings
4/03/2025
Today
5/08/2025
Fiscal Year End
5/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LFCR
Employees
690
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$10.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+14.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$12.01 million
Pretax Margin
-11.40%

Debt

Sales & Book Value

Annual Sales
$130.31 million
Price / Cash Flow
N/A
Book Value
$0.37 per share
Price / Book
18.91

Miscellaneous

Free Float
26,580,000
Market Cap
$258.99 million
Optionable
Optionable
Beta
0.65
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:LFCR) was last updated on 5/8/2025 by MarketBeat.com Staff
From Our Partners